The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TNX-102 SL (cyclobenzaprine HCL sublingual tablets) for the management of fibromyalgia.

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Tuesday after initially jumping after the company ...

U.S. industrial production declined by 0.1% from the previous month in November compared to a 0.4% drop in October, and versus market estimates of a 0.2% gain. Commodities In commodity news, oil ...

FDA accepts Tonix’s NDA for TNX-102 SL, a non-opioid fibromyalgia treatment. Learn how this potential new drug addresses ...

Tonix Pharmaceuticals Holding said the Food and Drug Administration has accepted its application seeking approval of its TNX-102 SL product candidate for the chronic pain condition fibromyalgia.

Tonix Pharma ( (TNXP) ) has provided an announcement.

Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration, FDA, has accepted the filing of its New Drug Application, ...

FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review ...

Charting, Price Performance, News & Related Contracts.

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies Granted ...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Corp. with ...

These strategic hires aim to enhance Tonix's commercial strategies and build its reputation in the medical community as the company awaits the FDA decision on TNX-102 SL in 2025. To view the full ...